當(dāng)前位置：   首頁(yè) > 需求大廳

各位智友：本人因檢測(cè)需要，求分享歐洲藥典10.0檢測(cè) General Chapters部分。應(yīng)包括以下內(nèi)容 2.2.32. Loss on drying 2.4.16. Total ash 2.8.1 Ash insoluble in hydrochloric acid 2.8.2 FOREIGN MATTER 2.2.13 WATER 2.8.4 SWELLING INDEX 2.8.15 BITTERNESS VALUE Appendix XI B1. Ethanol-soluble Extractive Appendix XI B2. Water-soluble Extractive   [更多]

本人由于研發(fā)需要，現(xiàn)想求購(gòu)全套中藥材生產(chǎn)基地信息，如果可以提供全套信息，價(jià)格面議，如果可以提供具體品種的中國(guó)種植基地信息，通過(guò)驗(yàn)證齊全且真實(shí)的，每個(gè)品種可以獲得500元信息服務(wù)獎(jiǎng)勵(lì)   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,”?International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010.?View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,”?American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011.?View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo?release of ciprofloxacin from ophthalmic formulations,”?International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011.?View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德國(guó)藥典   [更多]

當(dāng)心血管疾?。ㄐ呐K病或中風(fēng)）確診后，醫(yī)生會(huì)提供治療建議，但病人的決定是至關(guān)重要的。美國(guó)心臟協(xié)會(huì)（AHA）與 以病人為中心的成果研究所（PCORI）合作，網(wǎng)絡(luò)征集文章。你可以是患者，社區(qū)志愿者，家庭成員或任何人，只要你有這方面的親身經(jīng)驗(yàn)。根據(jù)你的情況來(lái)闡述患者的治療決策是怎樣做出的，例如：對(duì)壽命的影響，對(duì)生活質(zhì)量的影響，費(fèi)用，或其他？同時(shí)關(guān)心過(guò)程的完整性，時(shí)間，等等。。。 “請(qǐng)于2016年6月9日之前將稿件上傳到：https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other)   [更多]

Good Clinical Practice: A Question & Answer Reference Guide 2018 (Electronic)，電子版，要2018年版   [更多]

求購(gòu)海王藥業(yè)?；撬犷w粒（泰瑞寧）微生物檢測(cè)方法   [更多]

技術(shù)要求：我公司為精細(xì)化學(xué)品專業(yè)生產(chǎn)廠家，現(xiàn)閑置一整套手續(xù)齊全流水線車間，配備有先進(jìn)的生產(chǎn)設(shè)備和生產(chǎn)技術(shù)工人，現(xiàn)公司面向社會(huì)尋求技術(shù)合作。本公司熱忱歡迎社會(huì)各界朋友來(lái)廠洽談合作。   [更多]

1、要求提供的信息真實(shí)可靠。 2、要求直接提供賣家信息，不接受中介。 3、藥智技術(shù)轉(zhuǎn)讓數(shù)據(jù)庫(kù)里面沒(méi)有的信息。   [更多]

1.產(chǎn)品風(fēng)險(xiǎn)分析報(bào)告 2.產(chǎn)品技術(shù)要求 3.產(chǎn)品檢驗(yàn)報(bào)告 4.臨床評(píng)價(jià)資料 5.產(chǎn)品說(shuō)明書(shū)及標(biāo)簽樣稿 6.與產(chǎn)品研制、生產(chǎn)有關(guān)的質(zhì)量管理體系文件 7.生產(chǎn)制造信息 8.證明性文件 9.符合性聲明   [更多]

需要日本原研二甲硅油乳劑的質(zhì)量信息和檢驗(yàn)報(bào)告   [更多]